Spyre Therapeutics Management
Management criteria checks 0/4
Spyre Therapeutics' CEO is Cameron Turtle, appointed in Oct 2023, has a tenure of 1.08 years. total yearly compensation is $16.17M, comprised of 1.7% salary and 98.3% bonuses, including company stock and options. directly owns 1.27% of the company’s shares, worth €19.64M. The average tenure of the management team and the board of directors is 1.1 years and 1.4 years respectively.
Key information
Cameron Turtle
Chief executive officer
US$16.2m
Total compensation
| CEO salary percentage | 1.7% |
| CEO tenure | 1.1yrs |
| CEO ownership | 1.3% |
| Management average tenure | 1.1yrs |
| Board average tenure | 1.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$215m |
| Jun 30 2024 | n/a | n/a | -US$186m |
| Mar 31 2024 | n/a | n/a | -US$364m |
| Dec 31 2023 | US$16m | US$273k | -US$339m |
Compensation vs Market: Cameron's total compensation ($USD16.17M) is above average for companies of similar size in the German market ($USD1.65M).
Compensation vs Earnings: Insufficient data to compare Cameron's compensation with company performance.
CEO
Cameron Turtle (34 yo)
1.1yrs
Tenure
US$16,174,660
Compensation
Dr. Cameron Turtle, D.Phil, Ph D, joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023 and served until November 28, 2023 and serves as its Chief Executive Officer and Director at Spyre...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$16.17m | 1.27% € 19.6m | |
| Chief Financial Officer | 1.2yrs | US$7.55m | 0.026% € 399.9k | |
| Chief Legal Officer & Corporate Secretary | 1.2yrs | US$6.93m | 0% € 0 | |
| Senior Vice President of Operations | no data | no data | no data | |
| Chief Technical Officer | less than a year | no data | no data | |
| Vice President of Finance & Investor Relations | no data | no data | no data | |
| Vice President of Quality & Compliance | no data | no data | no data | |
| Senior Director of Corporate Communications & Investor Relations | no data | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Senior Vice President of People | no data | no data | no data | |
| Consultant | 1.5yrs | US$865.79k | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data |
1.1yrs
Average Tenure
44yo
Average Age
Experienced Management: 3920's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$16.17m | 1.27% € 19.6m | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Independent Chairman of the Board | less than a year | US$433.57k | 0.047% € 719.3k | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.2yrs | no data | no data | |
| Independent Director | 1.4yrs | US$658.43k | 0.69% € 10.7m | |
| Independent Director | less than a year | no data | 0% € 0 | |
| Independent Director | less than a year | US$434.38k | 0% € 0 | |
| Independent Director | 1.4yrs | US$660.78k | 0% € 0 | |
| Independent Director | 1.4yrs | US$661.28k | 0.69% € 10.7m |
1.4yrs
Average Tenure
44yo
Average Age
Experienced Board: 3920's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.